Cytek Biosciences Inc (CTKB) is a leader in multi-parameter flow cytometry, providing cutting-edge cell analysis solutions that propel advancements in the life sciences field. Their proprietary technologies are integral to critical research in immunology, cancer diagnostics, and drug development, meeting the increasing demand for precision in cellular analytics. With a commitment to innovation and exemplary customer support, Cytek strategically positions itself within the biotechnology sector, supported by a diverse product portfolio and a strong market presence. This foundation enables the company to drive transformative discoveries that significantly improve healthcare outcomes.
| Revenue (TTM) | $204.17M |
| Gross Profit (TTM) | $105.56M |
| EBITDA | $-36.30M |
| Operating Margin | -41.80% |
| Return on Equity | -20.90% |
| Return on Assets | -5.89% |
| Revenue/Share (TTM) | $1.60 |
| Book Value | $2.54 |
| Price-to-Book | 1.81 |
| Price-to-Sales (TTM) | 2.88 |
| EV/Revenue | 1.754 |
| EV/EBITDA | 222.69 |
| Quarterly Earnings Growth (YoY) | 73.50% |
| Quarterly Revenue Growth (YoY) | 6.50% |
| Shares Outstanding | $129.14M |
| Float | $96.58M |
| % Insiders | 8.41% |
| % Institutions | 67.45% |
Volatility is currently contracting
FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that the company will be participating in the upcoming Singular Research's Las Vegas Invitational Conference taking place June 14-16, 2026.
At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer.
Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript
FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026.
FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026.
